[go: up one dir, main page]

NO324473B1 - Substituerte arylpyraziner, anvendelse av slike for fremstilling av farmasoytisk preparat for behandling av sykdom, metode for a lokalisere CRF-reseptorer i vevsnittprover basert pa slike forbindelser, anvendelse av forbindelsene for a hemme, endre eller modulere reseptorfunksjoner, farmasoytisk preparat og pakket farmasoytisk prparat inneholdende disse forbindelsene. - Google Patents

Substituerte arylpyraziner, anvendelse av slike for fremstilling av farmasoytisk preparat for behandling av sykdom, metode for a lokalisere CRF-reseptorer i vevsnittprover basert pa slike forbindelser, anvendelse av forbindelsene for a hemme, endre eller modulere reseptorfunksjoner, farmasoytisk preparat og pakket farmasoytisk prparat inneholdende disse forbindelsene. Download PDF

Info

Publication number
NO324473B1
NO324473B1 NO20023869A NO20023869A NO324473B1 NO 324473 B1 NO324473 B1 NO 324473B1 NO 20023869 A NO20023869 A NO 20023869A NO 20023869 A NO20023869 A NO 20023869A NO 324473 B1 NO324473 B1 NO 324473B1
Authority
NO
Norway
Prior art keywords
alkyl
compound according
designation
amine
methoxy
Prior art date
Application number
NO20023869A
Other languages
English (en)
Norwegian (no)
Other versions
NO20023869L (no
NO20023869D0 (no
Inventor
Stephane De Lombaert
Kevin J Hodgetts
Taeyoung Yoon
Ping Ge
Raymond F Horvath
Dario Doller
Cunyu Zhang
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Publication of NO20023869D0 publication Critical patent/NO20023869D0/no
Publication of NO20023869L publication Critical patent/NO20023869L/no
Publication of NO324473B1 publication Critical patent/NO324473B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
NO20023869A 2000-02-16 2002-08-15 Substituerte arylpyraziner, anvendelse av slike for fremstilling av farmasoytisk preparat for behandling av sykdom, metode for a lokalisere CRF-reseptorer i vevsnittprover basert pa slike forbindelser, anvendelse av forbindelsene for a hemme, endre eller modulere reseptorfunksjoner, farmasoytisk preparat og pakket farmasoytisk prparat inneholdende disse forbindelsene. NO324473B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18293400P 2000-02-16 2000-02-16
US20645500P 2000-05-22 2000-05-22
PCT/US2001/005264 WO2001060806A2 (en) 2000-02-16 2001-02-16 Substituted arylpyrazines

Publications (3)

Publication Number Publication Date
NO20023869D0 NO20023869D0 (no) 2002-08-15
NO20023869L NO20023869L (no) 2002-09-11
NO324473B1 true NO324473B1 (no) 2007-10-29

Family

ID=26878562

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20023869A NO324473B1 (no) 2000-02-16 2002-08-15 Substituerte arylpyraziner, anvendelse av slike for fremstilling av farmasoytisk preparat for behandling av sykdom, metode for a lokalisere CRF-reseptorer i vevsnittprover basert pa slike forbindelser, anvendelse av forbindelsene for a hemme, endre eller modulere reseptorfunksjoner, farmasoytisk preparat og pakket farmasoytisk prparat inneholdende disse forbindelsene.

Country Status (33)

Country Link
US (3) US6995161B2 (is)
EP (1) EP1255740B1 (is)
JP (1) JP2004500383A (is)
KR (2) KR20080021603A (is)
CN (1) CN1231473C (is)
AP (1) AP2002002620A0 (is)
AT (1) ATE307121T1 (is)
AU (1) AU783915B2 (is)
BG (2) BG110174A (is)
BR (1) BR0108363A (is)
CA (2) CA2398937A1 (is)
CR (1) CR6735A (is)
CZ (1) CZ20022739A3 (is)
DE (1) DE60114153T2 (is)
DK (1) DK1255740T3 (is)
DZ (1) DZ3293A1 (is)
EA (1) EA006938B1 (is)
EE (1) EE200200453A (is)
ES (1) ES2247070T3 (is)
HR (1) HRP20020747A2 (is)
HU (1) HUP0301573A3 (is)
IL (1) IL151020A0 (is)
IS (1) IS2192B (is)
MA (1) MA26874A1 (is)
MX (1) MXPA02007868A (is)
NO (1) NO324473B1 (is)
NZ (1) NZ520484A (is)
OA (1) OA12178A (is)
PL (1) PL365238A1 (is)
SK (1) SK11542002A3 (is)
TW (1) TWI232215B (is)
WO (1) WO2001060806A2 (is)
YU (1) YU61002A (is)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024681A2 (en) 2000-09-20 2002-03-28 Ortho-Mcneil Pharmaceutical, Inc. Pyrazine derivatives as modulators of tyrosine kinases
PL367153A1 (en) * 2001-05-22 2005-02-21 Neurogen Corporation 5-substituted-2-arylpyridines as crf1 modulators
AP2003002924A0 (en) * 2001-06-12 2003-12-31 Neurogen Corp 2,5-diarylpyrazines, 2,5 - diarylpyridines and 2,5 - diarylpyrimidines as CRF1 receptor modulators
SE0102438D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0102439D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
US6852737B2 (en) * 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
ITMI20011726A1 (it) 2001-08-06 2003-02-06 Recordati Ind Chimica E Farma Forme polimorfe della lercanidipina cloridrato
AU2002343557A1 (en) * 2001-11-21 2003-06-10 Pharmacia And Upjohn Company Substituted aryl 1,4-pyrazine derivatives
US6992087B2 (en) 2001-11-21 2006-01-31 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
WO2003091225A1 (en) * 2002-04-26 2003-11-06 Pharmacia & Upjohn Company Substituted pyrazine derivatives
US7015227B2 (en) 2002-06-21 2006-03-21 Cgi Pharmaceuticals, Inc. Certain amino-substituted monocycles as kinase modulators
AU2003258307A1 (en) 2002-08-20 2004-03-11 Neurogen Corp 5-substituted-2-arylpyrazines as modulators of crf receptors
WO2004024719A1 (en) * 2002-09-12 2004-03-25 Pharmacia & Upjohn Company Llc Substituted 1,4-pyrazine derivatives
JP2006514628A (ja) * 2002-11-21 2006-05-11 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー Ｃｒｆ変調剤としてのピラジン化合物
SE0203754D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SE0203753D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
CN103265477B (zh) 2003-02-26 2017-01-11 苏根公司 作为蛋白激酶抑制剂的氨基杂芳基化合物
WO2004099201A1 (en) * 2003-05-09 2004-11-18 Pharmacia & Upjohn Company Llc Compounds as crf1 receptor antagonists
EP1625115A1 (en) 2003-05-09 2006-02-15 Pharmacia & Upjohn Company LLC Substituted pyrimidine derivatives
CN1812981A (zh) * 2003-06-27 2006-08-02 万有制药株式会社 杂芳氧基含氮饱和杂环衍生物
CA2543644A1 (en) * 2003-10-27 2005-05-06 Astellas Pharma Inc. Pyrazine derivatives and pharmaceutical use thereof
US20060211710A1 (en) * 2005-03-17 2006-09-21 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
TW200716594A (en) * 2005-04-18 2007-05-01 Neurogen Corp Substituted heteroaryl CB1 antagonists
KR101026676B1 (ko) * 2005-12-05 2011-04-04 화이자 프로덕츠 인코포레이티드 비정상 세포 성장의 치료 방법
EP1963302B1 (en) * 2005-12-05 2013-02-27 Pfizer Products Inc. Polymorphs of a c-met/hgfr inhibitor
SG157264A1 (en) * 2008-06-02 2009-12-29 Inzign Pte Ltd A golf tee and method of producing a golf tee
US7932256B2 (en) * 2008-07-31 2011-04-26 Bristol-Myers Squibb Company (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity
ES2702205T3 (es) 2014-02-14 2019-02-27 Takeda Pharmaceuticals Co Moduladores pirazínicos de GPR6
CN107567443B (zh) * 2014-12-24 2023-04-28 株式会社Lg化学 作为gpr120激动剂的联芳基衍生物
TWI806832B (zh) 2016-07-12 2023-07-01 美商銳新醫藥公司 作為異位shp2抑制劑之2,5-雙取代型3-甲基吡嗪及2,5,6-三取代型3-甲基吡嗪
BR112019014527A2 (pt) 2017-01-23 2020-02-27 Revolution Medicines, Inc. Compostos de piridina como inibidores de shp2 alostéricos
AU2018210770B2 (en) 2017-01-23 2022-03-24 Revolution Medicines, Inc. Bicyclic compounds as allosteric SHP2 inhibitors
RU2672470C1 (ru) * 2017-07-10 2018-11-15 Федеральное государственное бюджетное учреждение науки Институт нефтехимии и катализа Российской академии наук Способ получения 2,3,5,6-тетрафенил(бензил)пиразина
BR112020007058A2 (pt) 2017-10-12 2020-10-06 Revolution Medicines, Inc. compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos
WO2019118909A1 (en) 2017-12-15 2019-06-20 Revolution Medicines, Inc. Polycyclic compounds as allosteric shp2 inhibitors
JP2021522327A (ja) * 2018-04-20 2021-08-30 バージニア・テック・インテレクチュアル・プロパティーズ・インコーポレイテッドＶｉｒｇｉｎｉａ Ｔｅｃｈ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｉｅｓ， Ｉｎｃ． ミトコンドリア脱共役剤として有用なオキサジアゾロピラジンおよびオキサジアゾロピリジン
EP3982949A4 (en) * 2019-06-14 2023-10-11 Disarm Therapeutics, Inc. MRSA1 INHIBITORS
GB202006076D0 (en) * 2020-04-24 2020-06-10 Univ Greenwich Interleukin inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2425355A1 (de) 1974-05-25 1975-12-04 Basf Ag Verfahren zur herstellung von pyrazinen
SE421695B (sv) * 1975-04-21 1982-01-25 Merck & Co Inc Sett att framstella piperazinylpyraziner
FR2398738A1 (fr) * 1977-06-22 1979-02-23 Lilly Co Eli Preparation de benzoylurees
US4293552A (en) * 1978-02-27 1981-10-06 Eli Lilly And Company Novel 1-(mono-o-substituted benzoyl)-3-(substituted pyrazinyl) ureas
US4211870A (en) * 1979-04-06 1980-07-08 Eli Lilly And Company Preparation of substituted 2-aminopyrazines
JPS59144772A (ja) * 1983-02-08 1984-08-18 Ube Ind Ltd 液晶性ピラジン誘導体およびその製法
JPS625970A (ja) * 1985-03-15 1987-01-12 Terumo Corp ピラジン誘導体およびこれを含有する血小板凝集抑制剤
JPH0739398B2 (ja) * 1986-10-04 1995-05-01 宇部興産株式会社 液晶性ピラジン誘導体
NZ227684A (en) * 1988-01-30 1991-07-26 Merck Sharp & Dohme Pyrazine, pyridazine, and pyrimidine derivatives and pharmaceutical compositions
JPH0348666A (ja) 1989-07-17 1991-03-01 Rasa Kogyo Kk 芳香族ジアミン化合物の製造方法
DE3940477A1 (de) * 1989-12-07 1991-06-13 Bayer Ag Hetaryl-substituierte pyridinylpyrimidin-derivate
GB2272216A (en) * 1992-11-04 1994-05-11 Merck Patent Gmbh Liquid crystalline di-, tri- and tetra-fluorinated phenylpyrazines
CN1142817A (zh) * 1993-10-12 1997-02-12 杜邦麦克制药有限公司 1n-烷基-n-芳基嘧啶胺及其衍生物
AU7095496A (en) * 1995-09-26 1997-04-17 Nippon Soda Co., Ltd. Pyrazole compounds, process for preparing the same, and agrohorticultural bactericide
US6159980A (en) 1996-09-16 2000-12-12 Dupont Pharmaceuticals Company Pyrazinones and triazinones and their derivatives thereof
MA26473A1 (fr) 1997-03-01 2004-12-20 Glaxo Group Ltd Composes pharmacologiquement actifs.
BE1011077A3 (fr) 1997-03-28 1999-04-06 Univ Catholique Louvain Composition pharmaceutique, cosmetique et/ou alimentaire aux proprietes anti-oxydantes.
AU742641B2 (en) 1998-01-28 2002-01-10 Shionogi & Co., Ltd. Novel tricyclic compound
GB9818881D0 (en) * 1998-08-28 1998-10-21 Glaxo Group Ltd Compounds
CA2361561A1 (en) 1999-02-02 2000-08-10 K.U. Leuven Research & Development Immunosurpressive effects of pteridine derivatives

Also Published As

Publication number Publication date
DE60114153T2 (de) 2006-07-06
BG106968A (bg) 2003-04-30
IL151020A0 (en) 2003-02-12
HK1051191A1 (en) 2003-07-25
PL365238A1 (en) 2004-12-27
HUP0301573A2 (hu) 2003-12-29
MXPA02007868A (es) 2003-02-10
BR0108363A (pt) 2004-02-10
CA2398937A1 (en) 2001-08-23
EA006938B1 (ru) 2006-06-30
DK1255740T3 (da) 2006-02-06
IS6488A (is) 2002-07-29
EA200200766A1 (ru) 2003-10-30
NO20023869L (no) 2002-09-11
NZ520484A (en) 2005-03-24
YU61002A (sh) 2005-06-10
AP2002002620A0 (en) 2002-09-30
CZ20022739A3 (cs) 2003-02-12
WO2001060806A3 (en) 2002-02-07
US20050215559A1 (en) 2005-09-29
OA12178A (en) 2003-12-24
US20030018035A1 (en) 2003-01-23
BG110174A (en) 2009-05-29
KR20030031886A (ko) 2003-04-23
CR6735A (es) 2003-11-25
EE200200453A (et) 2003-12-15
WO2001060806A2 (en) 2001-08-23
IS2192B (is) 2007-01-15
EP1255740B1 (en) 2005-10-19
JP2004500383A (ja) 2004-01-08
HUP0301573A3 (en) 2004-03-29
US6995161B2 (en) 2006-02-07
US7202250B2 (en) 2007-04-10
MA26874A1 (fr) 2004-12-20
ES2247070T3 (es) 2006-03-01
CN1400970A (zh) 2003-03-05
AU783915B2 (en) 2005-12-22
DE60114153D1 (de) 2006-03-02
SK11542002A3 (sk) 2003-03-04
HRP20020747A2 (en) 2004-12-31
CN1231473C (zh) 2005-12-14
DZ3293A1 (fr) 2001-08-23
KR20080021603A (ko) 2008-03-07
TWI232215B (en) 2005-05-11
EP1255740A2 (en) 2002-11-13
ATE307121T1 (de) 2005-11-15
CA2651825A1 (en) 2001-08-23
US20070225287A1 (en) 2007-09-27
NO20023869D0 (no) 2002-08-15
AU3849401A (en) 2001-08-27

Similar Documents

Publication Publication Date Title
NO324473B1 (no) Substituerte arylpyraziner, anvendelse av slike for fremstilling av farmasoytisk preparat for behandling av sykdom, metode for a lokalisere CRF-reseptorer i vevsnittprover basert pa slike forbindelser, anvendelse av forbindelsene for a hemme, endre eller modulere reseptorfunksjoner, farmasoytisk preparat og pakket farmasoytisk prparat inneholdende disse forbindelsene.
RS61002B1 (sr) Formulacija rnk za imunoterapiju
US6887875B2 (en) 2,5-diarypyrimidine compounds
JP2004531570A (ja) Ｃｒｆ１モジュレーターとしての５−置換−２−アリールピリジン
CA2416248A1 (en) 5-substituted 2-aryl-4-pyrimidinones
US7179807B2 (en) 5-substituted-2-arylpyrazines
US20020072521A1 (en) 5-substituted arylpyrimidines
EP1500653A1 (en) Substituted arylpyrazines
AU2002310117A1 (en) 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines as CRF1 receptor modulators
ZA200206103B (en) Substituted arylpyrazines.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees